Videx/Videx EC (didanosine): Labeling Revision – Risk of Non-Cirrhotic Portal Hypertension

by FDA on February 6, 2010

in MedWatch

Risk information added to Warnings/Precautions section and data summary provided

This is a summary of an alert issued by MedWatch: The FDA Safety Information and Adverse Event Reporting Program. The link below will take you to the original notice.

View Full Details Of The Original MedWatch Notice Here.

Bookmark and Share

Leave a Comment

Previous post:

Next post: